CLINICAL TRIALS PROFILE FOR DANTROLENE SODIUM
✉ Email this page to a colleague
All Clinical Trials for DANTROLENE SODIUM
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02829268 ↗ | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | Active, not recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Phase 1/Phase 2 | 2017-01-01 | Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires. |
| NCT02829268 ↗ | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | Active, not recruiting | National Institutes of Health (NIH) | Phase 1/Phase 2 | 2017-01-01 | Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires. |
| NCT02829268 ↗ | A Clinical Trial of Dantrolene Sodium in Pediatric and Adult Patients With Wolfram Syndrome | Active, not recruiting | Washington University School of Medicine | Phase 1/Phase 2 | 2017-01-01 | Wolfram syndrome is a rare genetic disorder characterized by juvenile-onset diabetes mellitus, diabetes insipidus, optic nerve atrophy, hearing loss, and neurodegeneration. The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions. There is a screening period up to 56 days, a 6-month treatment period with an optional extension phase up to 24 months, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires. |
| NCT03762109 ↗ | The Use of Dantrolene to Improve Analgesia in Posterior Lumbar Surgery | Recruiting | Beth Israel Deaconess Medical Center | Phase 2 | 2019-07-29 | The purpose of this study is to determine whether administration of a non-centrally acting muscle relaxants will improve the Overall Benefit of Analgesia Score (OBAS), and Richmond Agitation Sedation Scale (RASS) scores in patients undergoing lumbar fusion. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for DANTROLENE SODIUM
Condition Name
Clinical Trial Locations for DANTROLENE SODIUM
Trials by Country
Clinical Trial Progress for DANTROLENE SODIUM
Clinical Trial Phase
Clinical Trial Sponsors for DANTROLENE SODIUM
Sponsor Name
| Sponsor Name for DANTROLENE SODIUM | |
| Sponsor | Trials |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 1 |
| National Institutes of Health (NIH) | 1 |
| Washington University School of Medicine | 1 |
| [disabled in preview] | 1 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
